Oncternal Debt To Assets from 2010 to 2024
| ONCT Stock | USD 0.71 0.43 37.72% |
Debt To Assets | First Reported 2010-12-31 | Previous Quarter 0.004098 | Current Value 0.003642 | Quarterly Volatility 0.0002553 |
Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 1.0E-4 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
Oncternal | Debt To Assets |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.